中國同輻(01763.HK):重慶高科取得正電子藥品生產資質
格隆匯 12 月 10日丨中國同輻(01763.HK)發佈公告,近日,原子高科股份有限公司(以下簡稱:原子高科)全資子公司——重慶原子高科醫藥有限公司(以下簡稱:重慶高科)順利取得北京市藥品監督管理局頒發的藥品委託生產批件(正電子類放射性藥品)。
重慶高科正電子藥品的投產運營,進一步完善了原子高科全國醫藥中心的網絡佈局,為原子高科放藥產業佈局增添了新的力量。重慶高科將以此次取得委託生產資質為契機,加強藥品生產的監督和管理,嚴格執行操作規程,嚴把藥品質量標準,忠實踐行“責任、安全、創新、協同”的核心價值觀,生產質量過硬的“放心藥”。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.